Open Access Government produces compelling and informative news, publications, eBooks, and academic research articles for the public and private sector looking at health, diseases & conditions, workplace, research & innovation, digital transformation, government policy, environment, agriculture, energy, transport and more.
Home 2024
Archives
Symptomatic vs. Disease-modifying treatments in neurological diseases: Where next?
An optimal drug for chronic neurological disease would slow down disease progression in the long term, with short-term symptomatic benefits. This would shorten clinical development timelines and reduce the cost and risk level for drug developers. Henri Huttunen Chief Scientific Officer (CSO) at Herantis Pharma Plc explains.
Exploring HER-096: A novel approach to Parkinson’s Disease
Parkinson’s disease, a progressive neurodegenerative disorder, poses significant challenges for both patients and researchers. In a recent interview with Henri Huttunen from Herantis Pharma Plc, we delved into the intricacies of their potential novel disease-modifying therapy, HER-096.
Herantis Pharma: Disease-modifying therapies for Parkinson’s disease
Herantis Pharma is an innovative biotech company developing disease-modifying therapies for Parkinson’s disease.
Progress in development of disease-modifying treatments in Parkinson’s Disease
Henri Huttunen, Chief Scientific Officer, Herantis Pharma Plc, charts progress in the development of disease-modifying treatments for Parkinson’s disease.
